Inhibition of NF-κB attenuates TRIM32-induced Bcl-2 upregulation and suggests its potential as a target to reduce resistance to cisplatin chemotherapy in NSCLC [40]. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.